Aarti Drugs · NSE: AARTIDRUGS · BSE: 524348
Q2 FY20 results · Jul–Sep 2019
Aarti Drugs reported revenue from operations of ₹477.50 crore (up 37.4% from Q2 FY19) and net profit of ₹32.31 crore (up 79.0% from Q2 FY19) for Q2 FY20 (Jul–Sep 2019), on a consolidated basis.
| Item | Q2 FY20 | Q2 FY19 | YoY | Q1 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 477.50 | 347.41 | +37.4% | 405.43 | +17.8% |
| Other income | 0.19 | 0.10 | +90.0% | 0.06 | +216.7% |
| Total income | 477.69 | 347.51 | +37.5% | 405.49 | +17.8% |
| Profit before tax | 47.86 | 26.73 | +79.0% | 33.63 | +42.3% |
| Net profit for the period | 32.31 | 18.05 | +79.0% | 22.45 | +43.9% |
| EPS, basic (₹) | 13.87 | 7.65 | +81.3% | 9.56 | +45.1% |
| Net margin (%) | 6.8 | 5.2 | 5.5 |
| Item | Q2 FY20 | Q2 FY19 | YoY | Q1 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 442.71 | 319.51 | +38.6% | 370.02 | +19.6% |
| Other income | 0.21 | 0.12 | +75.0% | 0.10 | +110.0% |
| Total income | 442.92 | 319.63 | +38.6% | 370.12 | +19.7% |
| Profit before tax | 45.80 | 26.68 | +71.7% | 32.32 | +41.7% |
| Net profit for the period | 30.80 | 18.03 | +70.8% | 21.57 | +42.8% |
| EPS, basic (₹) | 13.22 | 7.65 | +72.8% | 9.19 | +43.9% |
| Net margin (%) | 7.0 | 5.6 | 5.8 |
Consolidated
- Filed with BSE
- 29 Oct 2019, 11:24 IST
- Board meeting
- 23 Oct 2019
- Period
- 01 Jul 2019 to 30 Sep 2019
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 29 Oct 2019, 11:24 IST
- Board meeting
- 23 Oct 2019
- Period
- 01 Jul 2019 to 30 Sep 2019
- Review status
- Audited
- Source
- XBRL filing on BSE